The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator
Abstract Background Metabolic effects of empagliflozin treatment include lowered glucose and insulin concentrations, elevated free fatty acids and ketone bodies and have been suggested to contribute to the cardiovascular benefits of empagliflozin treatment, possibly through an improved cardiac funct...
Main Authors: | Roopameera Thirumathyam, Erik Arne Richter, Gerrit van Hall, Jens Juul Holst, Mogens Fenger, Jens P. Gøtze, Ulrik Dixen, Niels Vejlstrup, Sten Madsbad, Per Lav Madsen, Nils Bruun Jørgensen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-023-02094-x |
Similar Items
-
Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial
by: Jens Juul Holst, et al.
Published: (2022-08-01) -
Hyperinsulinemic Hypoglycemia Due to <i>PMM2</i> Mutation in Two Siblings with Autosomal Recessive Polycystic Kidney Disease
by: Ratna Acharya, et al.
Published: (2022-10-01) -
Fractionated free fatty acids and their relation to diabetes status after Roux‐en‐Y gastric bypass: A cohort study
by: Freja Eriksen, et al.
Published: (2021-01-01) -
Use of Noninsulin Anti Diabetics for Prevention and Treatment of Cancer- Narrative Review Article
by: Sadaf Raana, et al.
Published: (2015-02-01) -
Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters
by: P. Rosenbaum, et al.
Published: (2002-08-01)